首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1865614

生物蛋白藥物市場報告：趨勢、預測與競爭分析（至2031年）

Bio-Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

出版日期: 2025年11月10日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

全球生物蛋白藥物市場前景廣闊，製藥和生物技術公司、合約研究機構 (CRO) 以及學術界都蘊藏著巨大的機會。預計2025年至2031年，全球生物蛋白藥物市場將以8.9%的複合年成長率成長。推動該市場成長的關鍵因素包括：對標靶治療的需求不斷成長，從而促進了生物蛋白藥物的發展；以及生物技術的進步，從而推動了創新生物蛋白藥物的研發。

根據 Lucintel 的預測，單株抗體在預測期內有望實現高速成長。
從應用領域來看，製藥和生物技術公司預計將經歷更高的成長。
從區域來看，預計亞太地區在預測期內將達到最高的成長率。

生物蛋白製藥市場的新趨勢

生物蛋白製藥市場正經歷著變革，一些關鍵的新興趨勢正在重塑其格局。這些趨勢包括生物相似藥的創新、個人化醫療的興起以及先進技術在藥物研發中的應用。隨著對生物製藥需求的不斷成長，這些趨勢有望推動市場成長，改善患者療效，並顯著降低醫療成本。

生物相似藥的成長：市場對生物相似藥的需求日益成長，因為它們為昂貴的生物製藥提供了更經濟實惠的替代方案。包括FDA和EMA在內的全球監管機構正在簡化生物相似藥的核准流程，以促進其應用。隨著更多生物相似藥進入市場，競爭預計將降低價格，使更多患者能夠獲得治療。
個人化醫療：個人化醫療根據基因譜客製化治療方案，在生物蛋白製藥市場正日益受到關注。這種方法能夠實現更有效、更具針對性的治療，尤其是在腫瘤和自體免疫疾病領域。精準醫療的出現正在革新患者照護，在改善治療效果的同時，最大限度地減少傳統治療方法帶來的副作用。
藥物研發領域的技術創新：人工智慧 (AI) 和機器學習 (ML) 在藥物研發中的應用正在改變生物蛋白製藥市場。這些技術有助於識別潛在的治療標靶、最佳化藥物設計並預測患者反應，從而加速新型生物製藥的開發並提高臨床試驗的效率。
新興市場擴張：在印度和中國等慢性病盛行率不斷上升的新興市場，生物蛋白藥物的應用日益廣泛。經濟實惠的生物相似藥和本地化生產的增加正在改善這些地區生物製藥的可及性。預計這些市場中產階級的壯大和醫療改革將顯著推動對生物蛋白藥物的需求。
合作與策略聯盟：製藥公司正日益與生技公司和研究機構合作，共同開發創新生物蛋白藥物。這些合作使公司能夠獲得新技術，分擔研發成本，並加速新型生物製藥的商業化。策略聯盟正成為在生物蛋白藥物市場保持競爭優勢的關鍵因素。

生物相似藥的成長、個人化醫療、人工智慧藥物研發以及策略合作等新興趨勢正在重塑生物蛋白製藥市場。這些發展提高了生物製藥的可近性，改善了患者的治療效果，並提升了藥物研發的效率，為製藥業更具創新性和永續的未來鋪平了道路。

生物蛋白藥物市場的最新趨勢

生物蛋白藥物市場近期的發展趨勢反映出先進生物療法的日益普及，以及降低治療成本和提高治療可及性的迫切需求。重大技術創新和監管變革正在推動生物蛋白藥物在包括腫瘤、自體免疫疾病和代謝紊亂等多個治療領域的研發和商業化進程。

FDA核准新型單株抗體：FDA核准新型單株抗體標誌著癌症免疫療法取得了重大進展。這些生物製藥已顯示出治療多種癌症（包括淋巴瘤和黑色素瘤）的療效，也是腫瘤免疫療法選擇不斷擴展這一更廣泛趨勢的一部分。與傳統化療相比，這些核准為副作用較少的創新治療方法鋪平了道路。
基因和細胞療法的進展：基因和細胞療法在生物蛋白質製藥市場日益受到關注，尤其是在罕見遺傳疾病和癌症的治療領域。近期的突破性進展，例如基於 CRISPR 的療法和 CAR-T 細胞療法，已展現出令人鼓舞的成果。這些療法有望從基因層面治癒疾病，使其成為治療傳統上難以治癒疾病的極具創新性的治療方法。
生物相似藥市場擴張：生物相似藥市場持續擴張，越來越多的生物相似藥進入腫瘤、風濕病和糖尿病等治療領域。這些產品為品牌生物製藥提供了更實惠的替代方案，這在新興市場尤其重要。生物相似藥的持續核准和廣泛應用，使得生物蛋白藥物更容易取得。
對生物技術Start-Ups的投資：對生物技術Start-Ups的大量投資正在推動新型生物蛋白藥物的研發。創業投資和政府津貼正在支持生物製藥，尤其是在個人化醫療和罕見疾病等領域。這些投資正在加速新型治療方法的開發，並有助於擴大生物蛋白藥物的研發管線。
監管變革與加速核准：全球監管機構正在簡化生物蛋白藥物（尤其是生物相似藥和基因療法）的核准流程。在美國和歐洲，已推出相關舉措，旨在加快新生物製藥的審查，縮短其上市時間。這一趨勢有望促進患者更快獲得救命療法，並加劇市場競爭。

生物蛋白藥物市場的最新進展，包括FDA核准新型單株抗體、基因和細胞療法的興起以及生物相似藥的擴張，正在改變治療模式。這些進步推動了創新，提高了治療的可及性，並加速了針對多種疾病的最先進治療的研發。

The future of the global bio-protein drug market looks promising with opportunities in the pharma and biotech companies, cros, and academics markets. The global bio-protein drug market is expected to grow with a CAGR of 8.9% from 2025 to 2031. The major drivers for this market are the increasing demand for targeted therapies drives growth in bio-protein drugs. and the advancements in biotechnology enable the development of innovative bio-protein drugs.

Lucintel forecasts that, within the type category, monoclonal antibodies is expected to witness higher growth over the forecast period.
Within the application category, pharma and biotech companies is expected to witness the higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Bio-Protein Drug Market

The bio-protein drug market is evolving with key emerging trends that are reshaping its landscape. These trends include innovations in biosimilars, the rise of personalized medicine, and the integration of advanced technologies in drug discovery. As demand for biologics increases, these trends are expected to drive market growth, improve patient outcomes, and reduce healthcare costs ly.

Growth of Biosimilars: The demand for biosimilars is increasing as they offer a more affordable alternative to expensive biologic drugs. Regulatory agencies around the world, including the FDA and EMA, have streamlined approval processes for biosimilars, promoting their use. As more biosimilars enter the market, competition is expected to reduce prices and make treatments more accessible to patients ly.
Personalized Medicine: Personalized medicine, which tailors treatments based on genetic profiles, is gaining traction in the bio-protein drug market. This approach allows for more effective and targeted therapies, particularly in oncology and autoimmune diseases. The ability to deliver precision treatments is revolutionizing patient care, improving outcomes, and minimizing side effects associated with conventional therapies.
Technological Advancements in Drug Discovery: The integration of artificial intelligence (AI) and machine learning (ML) in drug discovery is transforming the bio-protein drug market. These technologies help in identifying potential therapeutic targets, optimizing drug design, and predicting patient responses. This is accelerating the development of new biologics and improving the efficiency of clinical trials.
Expansion in Emerging Markets: Bio-protein drugs are increasingly being adopted in emerging markets, such as India and China, where there is a rising prevalence of chronic diseases. Cost-effective biosimilars and increased local production are making biologics more accessible in these regions. The growing middle class and healthcare reforms in these markets are expected to drive significant demand for bio-protein drugs.
Collaboration and Strategic Partnerships: Pharmaceutical companies are increasingly forming partnerships with biotech firms and research institutions to co-develop innovative bio-protein drugs. These collaborations help companies to access new technologies, share research costs, and accelerate the commercialization of novel biologics. Strategic alliances are becoming a critical factor in staying competitive in the bio-protein drug market.

Emerging trends such as the growth of biosimilars, personalized medicine, AI-driven drug discovery, and strategic collaborations are reshaping the bio-protein drug market. These developments are making biologics more accessible, improving patient outcomes, and enhancing the efficiency of drug development, paving the way for a more innovative and sustainable future in the pharmaceutical industry.

Recent Developments in the Bio-Protein Drug Market

Recent developments in the bio-protein drug market reflect the increasing adoption of advanced biologic therapies and a focus on making treatments more affordable and accessible. Key innovations and regulatory changes are driving progress in the development and commercialization of bio-protein drugs across various therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders.

FDA Approval of New Monoclonal Antibodies: The approval of new monoclonal antibodies by the FDA has led to significant advancements in cancer immunotherapy. These biologics have shown efficacy in treating various cancers, including lymphoma and melanoma, and are part of a broader trend of expanding immunotherapy options in oncology. These approvals are paving the way for innovative treatments with fewer side effects compared to traditional chemotherapy.
Advances in Gene and Cell Therapies: Gene and cell therapies are gaining traction in the bio-protein drug market, particularly in treating rare genetic disorders and cancers. Recent breakthroughs, such as CRISPR-based therapies and CAR-T cell treatments, are offering promising results. These therapies hold the potential to cure diseases at the genetic level, making them highly innovative in the treatment of previously untreatable conditions.
Expansion of Biosimilars: The biosimilar market is expanding, with an increasing number of biosimilars entering the market across therapeutic areas such as oncology, rheumatology, and diabetes. These products are offering more affordable alternatives to branded biologics, which is especially important in emerging markets. The continued approval and uptake of biosimilars are making bio-protein drugs more accessible ly.
Investment in Biotech Startups: Significant investment in biotech startups is driving the development of new bio-protein drugs. Venture capital and government grants are supporting innovation in biologics, particularly in areas such as personalized medicine and rare diseases. These investments are helping to accelerate the development of novel therapies and expand the pipeline of bio-protein drugs.
Regulatory Changes and Faster Approvals: Regulatory bodies worldwide are streamlining the approval process for bio-protein drugs, particularly biosimilars and gene therapies. In the U.S. and Europe, initiatives have been introduced to speed up the review of novel biologics, reducing time to market. This trend is expected to facilitate faster access to life-saving therapies and encourage greater competition in the market.

Recent developments in the bio-protein drug market, such as FDA approvals for new monoclonal antibodies, the rise of gene and cell therapies, and the expansion of biosimilars, are transforming the treatment landscape. These advancements are driving innovation, making therapies more accessible, and accelerating the development of cutting-edge treatments for a wide range of diseases.

Strategic Growth Opportunities in the Bio-Protein Drug Market

The bio-protein drug market offers numerous growth opportunities, driven by increasing demand for biologics, advancements in biotechnology, and a focus on improving patient outcomes. Companies are capitalizing on these opportunities to develop innovative treatments for chronic and rare diseases while expanding into emerging markets.

Oncology Treatments: The increasing demand for personalized cancer therapies presents a significant growth opportunity. Bio-protein drugs, including monoclonal antibodies and immune checkpoint inhibitors, are revolutionizing cancer treatment by offering more targeted and effective options. Continued investment in research and clinical trials for cancer therapies is expected to fuel the market's growth in oncology.
Rheumatology and Autoimmune Diseases: Bio-protein drugs are seeing increasing adoption in treating autoimmune disorders such as rheumatoid arthritis, lupus, and psoriasis. The development of biologics like tumor necrosis factor (TNF) inhibitors and interleukin inhibitors is improving treatment outcomes. The growing prevalence of autoimmune diseases ly offers substantial opportunities for growth in this therapeutic area.
Metabolic Disorders: Bio-protein drugs are becoming key treatments for metabolic disorders such as diabetes and obesity. Insulin analogs and growth hormone therapies are just a few examples of biologics being used to manage these conditions. As the prevalence of diabetes rises, there is a significant opportunity for bio-protein drugs to address this growing health challenge.
Gene and Cell Therapy Innovations: Gene and cell therapies are a major area of growth, particularly for rare genetic diseases. The success of CAR-T cell therapies and gene editing technologies like CRISPR is driving the market. Companies investing in these therapies are positioned to capitalize on unmet medical needs and offer potential cures for conditions that were previously difficult or impossible to treat.
Expansion in Emerging Markets: The growing middle class and healthcare reforms in emerging markets, such as China and India, offer a significant opportunity for the bio-protein drug market. With increased access to healthcare and a rising prevalence of chronic diseases, these regions are expected to see a surge in demand for biologics, including biosimilars.

Strategic growth opportunities in oncology, rheumatology, metabolic disorders, gene therapy, and emerging markets are reshaping the bio-protein drug landscape. These areas offer significant potential for market expansion, innovation, and addressing unmet medical needs, driving continued growth in the bio-protein drug market.

Bio-Protein Drug Market Driver and Challenges

The bio-protein drug market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory hurdles. Understanding these drivers and challenges is crucial for stakeholders to navigate the complex landscape and capitalize on growth opportunities.

The factors responsible for driving the Bio-protein Drug market include:

1. Technological Advancements: Advancements in biotechnology, such as gene editing, protein engineering, and monoclonal antibody development, are driving the growth of the bio-protein drug market. These innovations are leading to the development of more effective and targeted treatments, improving patient outcomes.

2. Rising Demand for Personalized Medicine: As healthcare moves toward personalized medicine, bio-protein drugs are becoming key in providing tailored treatments. Genetic profiling and biomarker-based therapies are enabling more precise and effective treatments, fueling the demand for biologics.

3. Aging Population: The growing aging population is driving the demand for bio-protein drugs, particularly in the treatment of chronic conditions like cancer, diabetes, and autoimmune diseases. Older adults are more likely to require long-term biologic therapies, expanding market opportunities.

4. Regulatory Support for Biologics: Regulatory bodies are providing faster approval pathways for biologics, including biosimilars and gene therapies. This is helping to accelerate the development and availability of bio-protein drugs, increasing their adoption ly.

5. Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, is creating a strong demand for bio-protein drugs. These conditions require long-term treatment, creating a sustained need for biologics.

Challenges in the Bio-protein Drug market are:

1. High Production Costs: The high production costs of bio-protein drugs, especially biologics like monoclonal antibodies and gene therapies, pose a significant challenge. These costs can limit access to treatments, particularly in low-income regions, and put pressure on healthcare systems.

2. Regulatory Hurdles: While regulatory bodies have made strides in approving biologics, navigating complex regulations in different markets remains a challenge for companies. Variations in approval processes across regions can delay market entry and increase development costs.

3. Intellectual Property Issues: Patent expirations and intellectual property disputes over biosimilars and innovative biologics can create legal barriers. Companies need to protect their innovations while also addressing the growing competition from biosimilars.

Technological advancements, demand for personalized medicine, and increasing chronic disease prevalence are key drivers of the bio-protein drug market. However, challenges such as high production costs, regulatory hurdles, and intellectual property issues need to be addressed for sustained growth and market expansion.

List of Bio-Protein Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bio-protein drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bio-protein drug companies profiled in this report include-

Abbott Laboratories
Bayer AG
Eli Lilly and Company
Amgen Inc.
Biocon Ltd.
Dr. Reddy'S Laboratories
Roche

Bio-Protein Drug Market by Segment

The study includes a forecast for the global bio-protein drug market by type, application, and region.

Bio-Protein Drug Market by Type [Value from 2018 to 2031]:

Monoclonal Antibodies
Therapeutic Proteins
Vaccines

Bio-Protein Drug Market by Application [Value from 2018 to 2031]:

Pharma And Biotech Companies
Cros
Academics

Bio-Protein Drug Market by Region [Value from 2018 to 2031]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Bio-Protein Drug Market

The bio-protein drug market is experiencing rapid growth due to advancements in biotechnology, increased demand for personalized medicine, and the rising prevalence of chronic diseases. Bio-protein drugs, which include monoclonal antibodies, enzymes, and hormones, are revolutionizing treatments in areas such as cancer, autoimmune disorders, and diabetes. The United States, China, Germany, India, and Japan are leading regions, each showing distinct developments and trends that are shaping the future of this dynamic market.

United States: In the United States, the bio-protein drug market continues to grow, driven by advancements in immunotherapy, targeted treatments, and biosimilars. The Food and Drug Administration (FDA) has approved several new monoclonal antibodies and gene therapies, particularly for cancer and autoimmune diseases. Companies are focusing on developing personalized treatments tailored to genetic profiles. The increasing demand for biologics in the aging population and investments in biotech startups are fueling continued growth in this sector.
China: China is emerging as a leader in the bio-protein drug market due to its rapid advancements in biotechnology and favorable regulatory reforms. The Chinese government has introduced policies that support research and development, and several homegrown biotech companies are making significant strides in developing biosimilars and monoclonal antibodies. With an increasing demand for biologics driven by rising chronic disease rates, China is poised to be a key player in the bio-protein drug market.
Germany: Germany is a major hub for bio-protein drug development, with strong investments in research and manufacturing. The country's pharmaceutical and biotech sectors are focused on producing biosimilars, which are gaining traction due to their cost-effectiveness compared to original biologics. German companies are also leading efforts in the development of protein-based therapies for cancer, autoimmune diseases, and metabolic disorders. The integration of artificial intelligence and machine learning in drug development is expected to accelerate progress in Germany's bio-protein drug market.
India: India's bio-protein drug market is expanding rapidly, with a focus on affordable and accessible biologic treatments. The country's thriving pharmaceutical sector is producing a wide range of biosimilars, which are crucial for treating diseases like cancer, diabetes, and rheumatoid arthritis. India has become a manufacturing hub for bio-protein drugs, thanks to its low-cost production capabilities and increasing investments in biotechnology. The Indian government is also supporting the sector with initiatives to improve healthcare accessibility across the population.
Japan: Japan has a strong presence in the bio-protein drug market, with a focus on advanced biologics and monoclonal antibodies. The country's aging population is driving the demand for protein-based therapies, particularly in areas like cancer and diabetes treatment. Japanese companies are also exploring cutting-edge therapies, including gene and cell therapies, as part of the growing trend toward personalized medicine. Japan's efficient regulatory approval processes and high investment in healthcare are helping it maintain a competitive edge in the bio-protein drug sector.

Features of the Global Bio-Protein Drug Market

Market Size Estimates: Bio-protein drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Bio-protein drug market size by type, application, and region in terms of value ($B).
Regional Analysis: Bio-protein drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the bio-protein drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bio-protein drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the bio-protein drug market by type (monoclonal antibodies, therapeutic proteins, and vaccines), application (pharma and biotech companies, cros, and academics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Bio-Protein Drug Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Monoclonal Antibodies: Trends and Forecast (2019-2031)
4.4 Therapeutic Proteins: Trends and Forecast (2019-2031)
4.5 Vaccines: Trends and Forecast (2019-2031)

5. Global Bio-Protein Drug Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Pharma and Biotech Companies: Trends and Forecast (2019-2031)
5.4 CROs: Trends and Forecast (2019-2031)
5.5 Academics: Trends and Forecast (2019-2031)

6. Regional Analysis

6.1 Overview
6.2 Global Bio-Protein Drug Market by Region

7. North American Bio-Protein Drug Market

7.1 Overview
7.2 North American Bio-Protein Drug Market by type
7.3 North American Bio-Protein Drug Market by application
7.4 United States Bio-Protein Drug Market
7.5 Mexican Bio-Protein Drug Market
7.6 Canadian Bio-Protein Drug Market

8. European Bio-Protein Drug Market

8.1 Overview
8.2 European Bio-Protein Drug Market by type
8.3 European Bio-Protein Drug Market by application
8.4 German Bio-Protein Drug Market
8.5 French Bio-Protein Drug Market
8.6 Spanish Bio-Protein Drug Market
8.7 Italian Bio-Protein Drug Market
8.8 United Kingdom Bio-Protein Drug Market

9. APAC Bio-Protein Drug Market

9.1 Overview
9.2 APAC Bio-Protein Drug Market by type
9.3 APAC Bio-Protein Drug Market by application
9.4 Japanese Bio-Protein Drug Market
9.5 Indian Bio-Protein Drug Market
9.6 Chinese Bio-Protein Drug Market
9.7 South Korean Bio-Protein Drug Market
9.8 Indonesian Bio-Protein Drug Market

10. ROW Bio-Protein Drug Market

10.1 Overview
10.2 ROW Bio-Protein Drug Market by type
10.3 ROW Bio-Protein Drug Market by application
10.4 Middle Eastern Bio-Protein Drug Market
10.5 South American Bio-Protein Drug Market
10.6 African Bio-Protein Drug Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Bio-Protein Drug Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis
13.2 Abbott Laboratories
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 Bayer AG
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 Eli Lilly and Company
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Amgen Inc.
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Biocon Ltd.
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.7 Dr. Reddy'S Laboratories
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.8 Roche
- Company Overview
- Bio-Protein Drug Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

簡介目錄圖表

List of Figures

Figure 1.1: Trends and Forecast for the Global Bio-Protein Drug Market
Figure 2.1: Usage of Bio-Protein Drug Market
Figure 2.2: Classification of the Global Bio-Protein Drug Market
Figure 2.3: Supply Chain of the Global Bio-Protein Drug Market
Figure 3.1: Driver and Challenges of the Bio-Protein Drug Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Figure 4.1: Global Bio-Protein Drug Market by Type in 2019, 2024, and 2031
Figure 4.2: Trends of the Global Bio-Protein Drug Market ($B) by Type
Figure 4.3: Forecast for the Global Bio-Protein Drug Market ($B) by Type
Figure 4.4: Trends and Forecast for Monoclonal Antibodies in the Global Bio-Protein Drug Market (2019-2031)
Figure 4.5: Trends and Forecast for Therapeutic Proteins in the Global Bio-Protein Drug Market (2019-2031)
Figure 4.6: Trends and Forecast for Vaccines in the Global Bio-Protein Drug Market (2019-2031)
Figure 5.1: Global Bio-Protein Drug Market by Application in 2019, 2024, and 2031
Figure 5.2: Trends of the Global Bio-Protein Drug Market ($B) by Application
Figure 5.3: Forecast for the Global Bio-Protein Drug Market ($B) by Application
Figure 5.4: Trends and Forecast for Pharma and Biotech Companies in the Global Bio-Protein Drug Market (2019-2031)
Figure 5.5: Trends and Forecast for CROs in the Global Bio-Protein Drug Market (2019-2031)
Figure 5.6: Trends and Forecast for Academics in the Global Bio-Protein Drug Market (2019-2031)
Figure 6.1: Trends of the Global Bio-Protein Drug Market ($B) by Region (2019-2024)
Figure 6.2: Forecast for the Global Bio-Protein Drug Market ($B) by Region (2025-2031)
Figure 7.1: North American Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 7.2: Trends of the North American Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 7.3: Forecast for the North American Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 7.4: North American Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 7.5: Trends of the North American Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 7.6: Forecast for the North American Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 7.7: Trends and Forecast for the United States Bio-Protein Drug Market ($B) (2019-2031)
Figure 7.8: Trends and Forecast for the Mexican Bio-Protein Drug Market ($B) (2019-2031)
Figure 7.9: Trends and Forecast for the Canadian Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.1: European Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 8.2: Trends of the European Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 8.3: Forecast for the European Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 8.4: European Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 8.5: Trends of the European Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 8.6: Forecast for the European Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 8.7: Trends and Forecast for the German Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.8: Trends and Forecast for the French Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.9: Trends and Forecast for the Spanish Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.10: Trends and Forecast for the Italian Bio-Protein Drug Market ($B) (2019-2031)
Figure 8.11: Trends and Forecast for the United Kingdom Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.1: APAC Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 9.2: Trends of the APAC Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 9.3: Forecast for the APAC Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 9.4: APAC Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 9.5: Trends of the APAC Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 9.6: Forecast for the APAC Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 9.7: Trends and Forecast for the Japanese Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.8: Trends and Forecast for the Indian Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.9: Trends and Forecast for the Chinese Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.10: Trends and Forecast for the South Korean Bio-Protein Drug Market ($B) (2019-2031)
Figure 9.11: Trends and Forecast for the Indonesian Bio-Protein Drug Market ($B) (2019-2031)
Figure 10.1: ROW Bio-Protein Drug Market by type in 2019, 2024, and 2031
Figure 10.2: Trends of the ROW Bio-Protein Drug Market ($B) by type (2019-2024)
Figure 10.3: Forecast for the ROW Bio-Protein Drug Market ($B) by type (2025-2031)
Figure 10.4: ROW Bio-Protein Drug Market by application in 2019, 2024, and 2031
Figure 10.5: Trends of the ROW Bio-Protein Drug Market ($B) by application (2019-2024)
Figure 10.6: Forecast for the ROW Bio-Protein Drug Market ($B) by application (2025-2031)
Figure 10.7: Trends and Forecast for the Middle Eastern Bio-Protein Drug Market ($B) (2019-2031)
Figure 10.8: Trends and Forecast for the South American Bio-Protein Drug Market ($B) (2019-2031)
Figure 10.9: Trends and Forecast for the African Bio-Protein Drug Market ($B) (2019-2031)
Figure 11.1: Porter's Five Forces Analysis of the Global Bio-Protein Drug Market
Figure 11.2: Market Share (%) of Top Players in the Global Bio-Protein Drug Market (2024)
Figure 12.1: Growth Opportunities for the Global Bio-Protein Drug Market by Type
Figure 12.2: Growth Opportunities for the Global Bio-Protein Drug Market by Application
Figure 12.3: Growth Opportunities for the Global Bio-Protein Drug Market by Region
Figure 12.4: Emerging Trends in the Global Bio-Protein Drug Market

List of Tables

Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Bio-Protein Drug Market by Type and Application
Table 1.2: Attractiveness Analysis for the Bio-Protein Drug Market by Region
Table 1.3: Global Bio-Protein Drug Market Parameters and Attributes
Table 3.1: Trends of the Global Bio-Protein Drug Market (2019-2024)
Table 3.2: Forecast for the Global Bio-Protein Drug Market (2025-2031)
Table 4.1: Attractiveness Analysis for the Global Bio-Protein Drug Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Bio-Protein Drug Market (2019-2024)
Table 4.3: Market Size and CAGR of Various Type in the Global Bio-Protein Drug Market (2025-2031)
Table 4.4: Trends of Monoclonal Antibodies in the Global Bio-Protein Drug Market (2019-2024)
Table 4.5: Forecast for Monoclonal Antibodies in the Global Bio-Protein Drug Market (2025-2031)
Table 4.6: Trends of Therapeutic Proteins in the Global Bio-Protein Drug Market (2019-2024)
Table 4.7: Forecast for Therapeutic Proteins in the Global Bio-Protein Drug Market (2025-2031)
Table 4.8: Trends of Vaccines in the Global Bio-Protein Drug Market (2019-2024)
Table 4.9: Forecast for Vaccines in the Global Bio-Protein Drug Market (2025-2031)
Table 5.1: Attractiveness Analysis for the Global Bio-Protein Drug Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Bio-Protein Drug Market (2019-2024)
Table 5.3: Market Size and CAGR of Various Application in the Global Bio-Protein Drug Market (2025-2031)
Table 5.4: Trends of Pharma and Biotech Companies in the Global Bio-Protein Drug Market (2019-2024)
Table 5.5: Forecast for Pharma and Biotech Companies in the Global Bio-Protein Drug Market (2025-2031)
Table 5.6: Trends of CROs in the Global Bio-Protein Drug Market (2019-2024)
Table 5.7: Forecast for CROs in the Global Bio-Protein Drug Market (2025-2031)
Table 5.8: Trends of Academics in the Global Bio-Protein Drug Market (2019-2024)
Table 5.9: Forecast for Academics in the Global Bio-Protein Drug Market (2025-2031)
Table 6.1: Market Size and CAGR of Various Regions in the Global Bio-Protein Drug Market (2019-2024)
Table 6.2: Market Size and CAGR of Various Regions in the Global Bio-Protein Drug Market (2025-2031)
Table 7.1: Trends of the North American Bio-Protein Drug Market (2019-2024)
Table 7.2: Forecast for the North American Bio-Protein Drug Market (2025-2031)
Table 7.3: Market Size and CAGR of Various type in the North American Bio-Protein Drug Market (2019-2024)
Table 7.4: Market Size and CAGR of Various type in the North American Bio-Protein Drug Market (2025-2031)
Table 7.5: Market Size and CAGR of Various application in the North American Bio-Protein Drug Market (2019-2024)
Table 7.6: Market Size and CAGR of Various application in the North American Bio-Protein Drug Market (2025-2031)
Table 7.7: Trends and Forecast for the United States Bio-Protein Drug Market (2019-2031)
Table 7.8: Trends and Forecast for the Mexican Bio-Protein Drug Market (2019-2031)
Table 7.9: Trends and Forecast for the Canadian Bio-Protein Drug Market (2019-2031)
Table 8.1: Trends of the European Bio-Protein Drug Market (2019-2024)
Table 8.2: Forecast for the European Bio-Protein Drug Market (2025-2031)
Table 8.3: Market Size and CAGR of Various type in the European Bio-Protein Drug Market (2019-2024)
Table 8.4: Market Size and CAGR of Various type in the European Bio-Protein Drug Market (2025-2031)
Table 8.5: Market Size and CAGR of Various application in the European Bio-Protein Drug Market (2019-2024)
Table 8.6: Market Size and CAGR of Various application in the European Bio-Protein Drug Market (2025-2031)
Table 8.7: Trends and Forecast for the German Bio-Protein Drug Market (2019-2031)
Table 8.8: Trends and Forecast for the French Bio-Protein Drug Market (2019-2031)
Table 8.9: Trends and Forecast for the Spanish Bio-Protein Drug Market (2019-2031)
Table 8.10: Trends and Forecast for the Italian Bio-Protein Drug Market (2019-2031)
Table 8.11: Trends and Forecast for the United Kingdom Bio-Protein Drug Market (2019-2031)
Table 9.1: Trends of the APAC Bio-Protein Drug Market (2019-2024)
Table 9.2: Forecast for the APAC Bio-Protein Drug Market (2025-2031)
Table 9.3: Market Size and CAGR of Various type in the APAC Bio-Protein Drug Market (2019-2024)
Table 9.4: Market Size and CAGR of Various type in the APAC Bio-Protein Drug Market (2025-2031)
Table 9.5: Market Size and CAGR of Various application in the APAC Bio-Protein Drug Market (2019-2024)
Table 9.6: Market Size and CAGR of Various application in the APAC Bio-Protein Drug Market (2025-2031)
Table 9.7: Trends and Forecast for the Japanese Bio-Protein Drug Market (2019-2031)
Table 9.8: Trends and Forecast for the Indian Bio-Protein Drug Market (2019-2031)
Table 9.9: Trends and Forecast for the Chinese Bio-Protein Drug Market (2019-2031)
Table 9.10: Trends and Forecast for the South Korean Bio-Protein Drug Market (2019-2031)
Table 9.11: Trends and Forecast for the Indonesian Bio-Protein Drug Market (2019-2031)
Table 10.1: Trends of the ROW Bio-Protein Drug Market (2019-2024)
Table 10.2: Forecast for the ROW Bio-Protein Drug Market (2025-2031)
Table 10.3: Market Size and CAGR of Various type in the ROW Bio-Protein Drug Market (2019-2024)
Table 10.4: Market Size and CAGR of Various type in the ROW Bio-Protein Drug Market (2025-2031)
Table 10.5: Market Size and CAGR of Various application in the ROW Bio-Protein Drug Market (2019-2024)
Table 10.6: Market Size and CAGR of Various application in the ROW Bio-Protein Drug Market (2025-2031)
Table 10.7: Trends and Forecast for the Middle Eastern Bio-Protein Drug Market (2019-2031)
Table 10.8: Trends and Forecast for the South American Bio-Protein Drug Market (2019-2031)
Table 10.9: Trends and Forecast for the African Bio-Protein Drug Market (2019-2031)
Table 11.1: Product Mapping of Bio-Protein Drug Suppliers Based on Segments
Table 11.2: Operational Integration of Bio-Protein Drug Manufacturers
Table 11.3: Rankings of Suppliers Based on Bio-Protein Drug Revenue
Table 12.1: New Product Launches by Major Bio-Protein Drug Producers (2019-2024)
Table 12.2: Certification Acquired by Major Competitor in the Global Bio-Protein Drug Market

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

生物蛋白藥物市場報告：趨勢、預測與競爭分析（至2031年）

Bio-Protein Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

目錄

第1章執行摘要

第2章 市場概覽

第3章：市場趨勢與預測分析

第4章 全球生物蛋白藥物市場（按類型分類）

第5章 全球生物蛋白藥物市場（依應用領域分類）

第6章 區域分析

第7章：北美生物蛋白藥物市場

8. 歐洲生物蛋白製藥市場

9. 亞太地區生物蛋白藥物市場

第10章 世界其他地區（ROW）生物蛋白藥物市場

第11章 競爭分析

第12章：機會與策略分析

第13章：價值鏈中主要企業的概況

第14章附錄